What The Flu Shot's History Tells Us About Coronavirus Vaccines
Pfizer (NYSE: PFE) and its German partner BioNTech (NASDAQ: BNTX) reported incredible efficacy data from a phase 3 trial for their mRNA coronavirus vaccine candidate last Monday. While the 90% figure inspired much hope, investors should know this was interim data that have not yet been peer-reviewed. This week, Moderna (NASDAQ: MRNA) reported equally impressive results for its vaccine candidate that takes a similar approach.
The Motley Fool sat down with Dr. Jeremy Brown, author of Influenza: The Hundred-Year Hunt To Cure The Deadliest Disease In History and Director of Emergency Care Research at the National Institutes of Health. Dr. Brown shared how what we know about the flu vaccine will inform how coronavirus vaccines are understood.
Source Fool.com
